Comparative analysis of adverse events associated with epirubicin and doxorubicin: An observational study based on FDA Adverse Event Reporting System (FAERS) following STROBE guidelines
Open Access
- 2 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46929
Abstract
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.Keywords
Funding Information
- Henan provincial Medical Science and technology research program (NO.LHGJ20240293)
This publication has 35 references indexed in Scilit:
- Adriamycin-induced oxidative mitochondrial cardiotoxicityCell Biology and Toxicology, 2006
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patientsAnnals of Oncology, 2002
- Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.2000
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998
- Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine developmentBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1992
- Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.Journal of Biological Chemistry, 1986
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984
- Daunorubicin-DNA and doxorubicin-DNA a review of experimental and clinical dataCancer Chemotherapy and Pharmacology, 1979